Stock Track | 10x Genomics Plunges 10.85% After-Hours on Weak 2026 Revenue Outlook

Stock Track
Feb 13

10x Genomics Inc. (TXG) experienced a significant after-hours plunge, with its stock dropping 10.85% following the release of its fourth-quarter and full-year 2025 financial results.

The company reported Q4 earnings per share of $(0.13), beating analyst estimates, and revenue of $166.03 million, also surpassing expectations. However, investors reacted negatively to the company's 2026 revenue guidance, which projects revenue between $600 million and $625 million, implying only modest growth compared to 2025's total revenue of $642.82 million.

Analyst sentiment also contributed to the sell-off, with the median 12-month price target of $18.00 sitting below the stock's previous closing price, indicating limited upside potential according to Wall Street expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10